The effect of spironolactone versus eplerenone on blood pressure targets in resistant hypertension patients.

Back

ESC Professional Premium Access

The effect of spironolactone versus eplerenone on blood pressure targets in resistant hypertension patients.

Session: Secondary and resistant hypertension

Topic: Pharmacotherapy

Speaker: Professor L. Mishchenko (Kiev, UA)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Professor Larysa Mishchenko

Strazhensku Cardiology Institute, Kiev (Ukraine)

1 follower

8 more presentations in this session

Prediction of outcome in malignant hypertension patients using machine learning: a report from the West Birmingham malignant hypertension registry

Speaker: Doctor A. Argyris (Athens, GR)

Ten-year outcomes in patients with hypertension and primary hyperaldosteronism undergoing surgical adrenalectomy versus medical therapy: data from the multinational collaborative network TriNetX

Speaker: Doctor R. Belo Nunes (Sao Paulo, BR)

Cerebral damage after malignant hypertensive crisis: cerebral MRI follow-up data

Speaker: Doctor J. Liegey (Bordeaux, FR)

Impaired systemic microvascular function in patients with resistant arterial hypertension and microalbuminuria: an observational study

Speaker: Doctor E. Tibirica (Rio de Janeiro, BR)

Semaglutide for the treatment of resistant hypertension

Speaker: Doctor C. Kennedy (Dublin, IE)

Access the full session

Secondary and resistant hypertension

Speakers: Professor L. Mishchenko, Doctor A. Argyris, Doctor R. Belo Nunes, Doctor J. Liegey, Doctor E. Tibirica...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources